People: Aegerion Pharmaceuticals Inc (AEGR.O)
61.57USD
17 May 2013
$-0.13 (-0.21%)
$61.70
$61.73
$62.69
$58.83
1,792,712
625,898
$63.72
$12.86
Scheer, David
Brief Biography
Mr. David I. Scheer is Independent Chairman of the Board of Aegerion Pharmaceuticals Inc., since February 2005. He is a co-founder of Aegerion. Since 1981, Mr. Scheer has served as President at Scheer & Company, Inc., a company that provides corporate strategic advisory services in the life sciences industry. Mr. Scheer serves as the Chairman of the Board of Tengion, Inc. and Achillion Pharmaceuticals, Inc. Mr. Scheer also serves on the boards of directors of several private companies. Mr. Scheer is also a member of the Advisory Committee to the Harvard Malaria Initiative and the Leadership Council for the Harvard School of Public Health. Mr. Scheer holds an A.B. cum laude from Harvard College and an M.S. from Yale University.
Basic Compensation
| Total Annual Compensation, | Long-Term Incentive Plans, | All Other, | Fiscal Year Total, |
|---|---|---|---|
| -- | -- | -- | -- |
Options Compensation
| Quantity | Market Value | |
|---|---|---|
| Excercisable | -- | -- |
| Unexercisable | -- | -- |
| Excercised | -- | -- |
| Name | Fiscal Year Total |
|---|---|
David Scheer |
-- |
Marc Beer |
2,131,520 |
Mark Fitzpatrick |
3,083,000 |
Anne Cook |
-- |
Martha Carter |
2,002,280 |
Mark Sumeray |
1,998,130 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
